Risk Still OFF with Euro Malaise
Look for biotechnology intermediate top as we approach ASCO next week. Market is now driven by hedgies and big funds.IBB ($123.90) double top with YTD high of $126.90 Mid cap biotech index off 1.7%. DX and tools also very weak. S&P unchanged from one year...
Notes from B Riley 13th Annual Investor Conference: CEMI,VRML
There were some excellent small cap companies presenting at the B. Riley Investor Conference in Santa Monica this week. Five tracks covered companies in healthcare, technology and energy, consumer/telecom, software and services and internet and media. Our focus within healthcare is...
Todays’ Sell-Off Finally Hits Resilient Biotech Stocks
Facebook Hype Effect-Sell MO Stocks? Many of the favorite momentum stocks are being hit with profit taking today including large cap biopharmaceutical stocks. With the NASDAQ down 0.8% at 2850, we see a lot of countertrends like gold up $39.70 off recent lows to $1576 accompanied by a big...
Biotech Sector Avoids Nasty Correction and Hits New Highs
Why is the biotechnology sector still strong? Despite all the gloom and doom in the markets over the past 60 days the biotechnology sector has barely flinched and is currently at YTD highs. Bellwether ETFs IBB (126) and XBI ($82.85) are up over 20% YTD after a brief correction in mid-April...
Rayno Life Science -Biomarkers: BGMD,VRML
Biomarker MicroCap Face-Off: BGMD vs VRML Vermillion announced Q1 Results today today with OVA1 revenues of $312K of which $114 k was licensing revenues from their testing partner Quest Diagnostics Inc.(DGX $57). Operating expenses were down to $2.4M compared to$4.8M in the same period a year...